佐他莫司|T6033|TargetMol

價格	￥413	￥892	￥1530
包裝	1mg	5mg	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2026-06-29

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:佐他莫司	英文名稱:Zotarolimus
CAS:221877-54-9	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Store at low temperature,Keep away from moisture Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
純度規(guī)格: 98.01%	產(chǎn)品類別: 抑制劑
貨號: T001\|T6033

Product Introduction

Bioactivity

名稱	Zotarolimus
描述	Zotarolimus (ABT-578), an analogue of rapamycin, inhibits FKBP-12 (IC₅₀= 2.8 nM).
細(xì)胞實驗	Cell proliferation is assayed by measuring tritiated thymidine incorporation in vitro. Human coronary artery cells (hCa) are seeded into tissue culture flasks for expansion and applied to 96-well plates at desired density in complete media (5000 hCaSMC; 10 000 hCaEC). After 2 days, complete media is replaced with incomplete media to synchronize cells and induce G0 state. Two days later, incomplete media are removed and replaced with complete media (serum/growth factors) to induce G0 to G1 transition. Complete media also contain drug at desired concentrations to determine its effects on cell proliferation. On day 7, 3H-thymidine is added to cells to monitor DNA synthesis, and cells are harvested after overnight incorporation of radioactivity. After an incubation period of 72 h, 25 μL (1 μCi/well) of 3H-thymidine are added to each well. The cells are incubated at 37°C for 16-18 h to allow for incorporation of 3H-thymidine into newly synthesized DNA and the cells harvested onto 96-well plates containing bonded glass fibre filters . The filter plates are air-dried overnight, MicroScint-20 (25 μL) added to each filter well and counted. Drug activity is determined by the inhibition of 3H-thymidine incorporation into newly synthesized DNA relative to cells grown in complete media. (Only for Reference)
激酶實驗	zotarolimus (10 pM-1 μM) in buffer A (2% BSA and 0.2% Tween-20 in D-PBS) is used in the assay of Binding Affinity to FKBP12.
動物實驗	Male Sprague-Dawley rats was administrate by intravenous or oral Zotarolimus（2.5 mg/kg）dissolved inethanol: propylene glycol: cremophor EL: D5W vehicle (20: 30: 2: 48, by volume).
體外活性	在平滑肌細(xì)胞（IC50=2.9 nM）和內(nèi)皮細(xì)胞（IC50=2.6 nM）中，Zotarolimus有效抑制細(xì)胞增殖。
體內(nèi)活性	Zotarolimus 強效抑制劑，對輔助性遲發(fā)型超敏反應(yīng)(DTH)(ED50=1.72 mg/kg/day)、實驗性自身免疫性腦炎(EAE)(ED50=1.17 mg/kg/day)、以及心臟移植排斥反應(yīng)(ED50=3.71 mg/kg/day)表現(xiàn)出顯著的抑制作用。
存儲條件	Store at low temperature,Keep away from moisture Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
溶解度	10% DMSO+90% Corn Oil : 3.3 mg/mL (3.42 mM), Sonication is recommended. Ethanol : 93 mg/mL (96.25 mM), Sonication is recommended. DMSO : 93 mg/mL (96.25 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble)
關(guān)鍵字	Zotarolimus \| stents \| restenosis \| Rapamycin \| Inhibitor \| inhibit \| immunosuppressant \| FKBP-12 \| drug-eluting \| disease \| coronary \| artery \| ABT578 \| ABT 578 \| A-179578 \| A179578
相關(guān)產(chǎn)品	L-Proline \| Metformin \| Rapamycin \| Pyraclostrobin \| Resveratrol \| Methyl eugenol \| L-Leucine \| Dihydromyricetin \| N-Hydroxyphthalimide \| Acesulfame Potassium \| Stearamide \| 4-Vinylcyclohexene Dioxide
相關(guān)庫	抗癌細(xì)胞代謝庫 \| 抗感染化合物庫 \| FDA上市及藥典收錄分子庫 \| HIF-1化合物庫 \| NO PAINS 化合物庫 \| 抗肝癌化合物庫 \| 抗肥胖化合物庫 \| 表型篩選靶點鑒定庫

關(guān)鍵字：咗他莫司;佐他莫司;ABT-578;A 179578;TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計算機輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （14年）	注冊資本	566.265100萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 5年

公司成立：14年
注冊資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場三路238號8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 CL 218872|T8572|TargetMol

￥121

雷尼司他|T16723|TargetMol

￥1370

化合物 TG-46|T20743|TargetMol

詢價